A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.

Registry ID

EUCTR2004-004150-51

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Pfizer Limited

Start date

2004-12-10

Completion date

2005-07-28

Last update

2026-08-16

Conditions

• Premature Ejaculation

Summary

The primary objective of this study is to investigate the safety and efficacy of the UK-390,957 individual flexible dose group (including doses up to 10 mg) compared to placebo. Efficacy will be assessed using IELT at Week 8 and adverse events will be summarized by treatment arm.

Locations

• , , UK

Related clinical trials

• Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
• Pelvic Floor Therapies for Lifelong Premature Ejaculation
• The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation
• Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
• Ejaculatory and Orgasmic Dysfunction Registry
• Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients

View on source registry